Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $3.95 -2.47%
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $64.5 million versus the consensus estimate of $67.6 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- Infosys Limited (INFY) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
